KLRS vs IMVT vs JPM vs RCUS vs KYMR

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -52. 5% for Kalaris Therapeutics Inc (KLRS). Over 10 years, the gap is even starker: JPM returned +465. 8% versus KLRS's -52. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kalaris Therapeutics Inc (KLRS) is the lower-risk stock at 0.

81β versus Arcus Biosciences, Inc. 's 2. 00β — meaning RCUS is approximately 146% more volatile than KLRS relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 3. 3% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Kalaris Therapeutics Inc grew EPS 75. 7% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for KLRS: 331.

2% to $18. 67.

In this comparison, JPM (1.

9% yield) pays a dividend. KLRS, IMVT, RCUS, KYMR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, RCUS: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (KLRS (Healthcare) and IMVT (Healthcare) and JPM (Financial Services) and RCUS (Healthcare) and KYMR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: KLRS is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; RCUS is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock. JPM pays a dividend while KLRS, IMVT, RCUS, KYMR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.